Clinical trials: Advanced Non-small Cell Lung Cancer
Non-Small Cell Lung Cancer
Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib
This is a randomized, open-label, multi-center, Phase II study of treatment of patients with advanced NSCLC who have progressed on erlotinib with the combination of sorafenib and erlotinib or sorafenib alone.
- Trial name
- NCT00609804
- Testing
- Sorafenib, Erlotinib
- Where
- 16 sites in United States
- Volunteers
- 53 people
- Sponsor
- SCRI Development Innovations, LLC
Non-small Cell Lung Cancer
A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer
This study is researching an investigational drug called fianlimab (also called REGN3767) with two other medications called cemiplimab and chemotherapy, individually called a "study drug" or collectively called "study drugs".
- Trial name
- NCT05800015
- Testing
- fianlimab, cemiplimab, Pemetrexed
- Where
- 76 sites in United States, Australia and 8 more
- Volunteers
- 160 people
- Sponsor
- Regeneron Pharmaceuticals
Solid Tumors, Non-Small Cell Lung Cancer
Phase Ib Trial of HS-20117 in Combination With Other Drugs in Advanced Solid Tumors
HS-20117 is a fully-human EGFR-MET immunoglobulin G1(IgG1)-like bispecific antibody. The purpose of study is to evaluate the safety, tolerability, efficacy, PK profile and immunogenicity of HS-20117 in combination with other…
- Conditions
- Solid Tumors, Non-Small Cell Lung Cancer, Colorectal Cancer
- Trial name
- HS-20117 (NCT06621563)
- Testing
- HS-20117 combined HS-20093, HS-20117 combined Platinum-containing chemotherapy, HS-20117 combined HS-20093 and 5-FU
- Where
- China
- Volunteers
- 780 people
- Sponsor
- Hansoh BioMedical R&D Company
Advanced Lung Carcinoma, Non-small Cell Lung Cancer
Efficacy and Safety of First-line Anti-PD-1/PD-L1 Monoclonal Antibody in Combination With Chemotherapy and Bronchoscopy-assisted Interventional Therapy in Patients With Advanced Central Non-small Cell Lung Cancer
Lung cancer is one of the malignant tumors with high morbidity and mortality. Several PD-1/PD-L1 immune checkpoint inhibitors have been approved for the treatment of advanced non-small cell lung cancer (NSCLC).
- Trial name
- NCT04702009
- Testing
- Chemoimmunotherapy (CIT): Sintilimab + Platinum-Based Doublet Chemotherapy
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Non-small Cell Lung Cancer
Phase I Multicenter Trial Combining Nivolumab, Ipilimumab and Hypo-fractionated Radiotherapy for Pretreated Advanced Stage Non-small Cell Lung Cancer Patients
Nivolumab is superior to docetaxel monotherapy as second line treatment in advanced stage non-small cell lung cancer (NSCLC) patients.
- Trial name
- NCT03509584
- Testing
- hypofractionated radiotherapy, nivolumab, Ipilimumab
- Where
- France
- Volunteers
- 6 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Non-small Cell Lung Cancer Metastatic
A Study of First Line Treatment With Tarceva (Erlotinib) in Combination With Gemcitabine in Patients With Unresectable Advanced and/or Metastatic Non-Small Cell Lung Cancer
This single arm study will assess the efficacy and safety of erlotinib + gemcitabine in chemotherapy-naive participants with unresectable, advanced and/or metastatic non-small cell lung cancer.
- Trial name
- NCT00701558
- Testing
- Erlotinib, Gemcitabine
- Where
- Romania
- Volunteers
- 20 people
- Sponsor
- Hoffmann-La Roche
Non-Small Cell Lung Cancer
A Study of Pemetrexed Plus Carboplatin Combined With Radiation in Patients With Inoperable Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC) (RT0801)
Patients with inoperable Non-Small-Cell Lung Cancer will receive thoracic radiation therapy 66 Gy over 33 fractions,and concurrent with 2 cycles of chemotherapy with pemetrexed (500 mg/m2,d1,repeated every 3 weeks)and carboplatin…
- Trial name
- NSCLC (NCT00886678)
- Testing
- pemetrexed, carboplatin, thoracic radiation
- Where
- China
- Volunteers
- 63 people
- Sponsor
- Zhejiang Cancer Hospital
Advanced Non-Small Cell Lung Cancer
Lorlatinib in ALK Inhibitor Treated Unresectable Advanced/Recurrent ALK-Positive Non Small Cell Lung Cancer Patients in India
Lorlatinib is a third-generation, oral, reversible, ATP-competitive, macrocyclic TKI of ALK and ROS1. Lorlatinib was specifically designed to penetrate the CNS and to overcome known secondary resistance mutations in the ALK…
- Trial name
- NCT04541706
- Testing
- Lorlatinib
- Where
- 12 sites in India
- Volunteers
- 100 people
- Sponsor
- Pfizer
Non-small Cell Lung Cancer
Parp Inhibitor in Advanced Non-Small Cell Lung Cancer (PIN)
In 2010, more than 35,000 people died in the United Kingdom from lung cancer, the majority from non-small cell cancer (NSCLC). Chemotherapy is one of the main treatments for patients with NSCLC but those treated will still only…
- Trial name
- PIN (NCT01788332)
- Testing
- Olaparib
- Where
- 20 sites in United Kingdom
- Volunteers
- 70 people
- Sponsor
- Lisette Nixon
Neoplasms
A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)
This is a first-in-human study evaluating the anti-T cell immunoglobulin and mucin containing protein-3 (TIM-3) antibody TSR-022.
- Trial name
- NCT02817633
- Testing
- TSR-022, Nivolumab, TSR-042
- Where
- 89 sites in United States, South Korea and 1 more
- Volunteers
- 463 people
- Sponsor
- Tesaro, Inc.
Non Small Cell Lung Cancer
Influence of the Use of the Diabetic Drug Metformin on the Overall Survival and Treatment-related Toxicity in Advanced Stage Non-small Cell Lung Cancer Patients.
There are preliminary data suggesting that patients suffering from non-insulin-dependent diabetes mellitus, treated with metformin, have improved local tumor control.
- Trial name
- Metformin (NCT02109549)
- Where
- 3 sites in Netherlands
- Volunteers
- 70 people
- Sponsor
- Maastricht Radiation Oncology
Advanced Non Small Cell Lung Cancer
Almonertinib Plus Microwave Ablation in Advanced Non-small Cell Lung Cancer
Almonertinib, as a third-generation EGFR-TKI, has been used for the treatment of advanced non small cell lung cancer. How to improve the progression free survival in advance was a challenge.
- Trial name
- MWA (NCT04755738)
- Testing
- Almonertinib plus microwave ablation
- Where
- China
- Volunteers
- 234 people
- Sponsor
- Qianfoshan Hospital
Breast Neoplasms, Carcinoma, Non-Small-Cell Lung
A Phase I Study of [68Ga]Ga-DWJ155 in Patients With Breast and Lung Cancers
This is a phase I, open label first in human study to evaluate the imaging performance, safety, biodistribution and pharmacokinetics of [68Ga]Ga-DWJ155 in patients ≥ 18 years of age with hormone receptor positive/HER2 negative…
- Trial name
- NCT07117214
- Testing
- [68Ga]Ga-DWJ155
- Where
- Netherlands
- Volunteers
- 36 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Non-squamous NSCLC
A BRIDGING STUDY OF PF-06439535 (CN) PLUS PACLITAXEL-CARBOPLATIN VERSUS BEVACIZUMAB PLUS PACLITAXEL-CARBOPLATIN IN NSCLC
The current study will compare the efficacy, safety, pharmacokinetics and immunogenicity of PF-06439535 (CN) in combination with paclitaxel and carboplatin versus bevacizumab sourced from the European Union (bevacizumab-EU) with…
- Trial name
- NCT04325698
- Testing
- PF-06439535 (CN), Bevacizumab-EU, Paclitaxel
- Where
- 4 sites in China
- Volunteers
- 8 people
- Sponsor
- Pfizer
Advanced Solid Tumor Historically Known for High EphA2 Expression, Urothelial Cancer
Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression
This clinical trial is evaluating a drug called BT5528 alone and in combination with nivolumab in participants with advanced solid tumors historically known for expression of EphA2.
- Conditions
- Advanced Solid Tumor Historically Known for High EphA2 Expression, Urothelial Cancer, Ovarian Cancer, Non-small Cell Lung Cancer
- Trial name
- NCT04180371
- Testing
- BT5528, Nivolumab
- Where
- 28 sites in United States, Belgium and 3 more
- Volunteers
- 288 people
- Sponsor
- BicycleTx Limited
Non Small Cell Lung Cancer
Efficacy and Safety of T-DXd in HER2-mutant Advanced Lung Cancer Patients With Asymptomatic Brain Metastases
'1. Objective Primary objective Median Intracranial Progression-free survival(icPFS) as defined by RANO(Response Assessment in Neuro-Oncology) criteria Secondary objective Progression free survival(PFS) as defined by RECIST 1.1…
- Trial name
- ELPIS (NCT06250777)
- Testing
- Trastuzumab deruxtecan
- Where
- South Korea
- Volunteers
- 27 people
- Sponsor
- Yonsei University
Advanced Solid Tumors, Non-small Cell Lung Cancer
Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer
This is the first human study to use X-396 (ensartinib), a drug being developed for treatment of advanced cancers. The initial purpose of the study is to determine the largest amount of X-396 that can be safely given to humans…
- Trial name
- NCT01625234
- Testing
- Phase I: X-396 (ensartinib), Phase II: X-396 (ensartinib)
- Where
- 14 sites in United States
- Volunteers
- 131 people
- Sponsor
- Xcovery Holdings, Inc.
Non Small Cell Lung Cancer, Breast Cancer
Analysis of PD-L1, TMB, MSI and ctDNA Dynamics to Predict and Monitor Response to Immunotherapy in Metastatic Cancer.
This is an observational clinical trial, aiming to investigate whether the ctDNA dynamics could predict early response to ICIs in patients with advanced-stage cancer.
- Conditions
- Non Small Cell Lung Cancer, Breast Cancer, Colorectal Cancer, Gastric Cancer
- Trial name
- PTC-IMPACT (NCT06227728)
- Where
- 2 sites in Vietnam
- Volunteers
- 50 people
- Sponsor
- Gene Solutions
NSCLC
Phase Ib Study of FURMONERTINIB in Patients with NSCLC Having Exon 20 Insertion Mutation
This is a phase 1 multi-center clinical study. To explore the efficacy and safety of Furmonertinib Mesilate at different doses in locally advanced or metastatic NSCLC patients with EGFR exon 20 insertion mutation.
- Trial name
- NCT04958967
- Testing
- Furmonertinib 240mg, Furmonertinib 160mg
- Where
- China
- Sponsor
- Allist Pharmaceuticals, Inc.
Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations
The purpose of this study is to compare the effectiveness of YK-029A as first-line treatment with that of platinum-based chemotherapy in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose…
- Trial name
- NCT05767892
- Testing
- YK-209A tablet, Pemetrexed+carboplatin/Cisplatin
- Where
- 52 sites in China
- Volunteers
- 350 people
- Sponsor
- Suzhou Puhe Pharmaceutical Technology Co., LTD